CO102 Physician Reported Treatment Attributes Considered in First-Line and Perceptions Around Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the US

This study assesses physicians ’ perception and rationales for treatment choices in patients with CLL/SLL in the US.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: C. Jensen, Z. Ding, T. Greenwood, C. Kluth, I. Sanderson, N. Milloy, H. Mavani, W. Khan, Z.P. Qureshi Source Type: research